BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 28
- Registration Number
- NCT00568945
A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT00568412
- Locations
- 🇩🇪
Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum, Bonn, Germany
Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1887
- Registration Number
- NCT00567164
Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT00566384
Single Dose Escalation Study in Patients With Chronic Heart Failure
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT00565565
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 21
- Registration Number
- NCT00562913
Sorafenib/Docetaxel Dose Escalation Trial
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT00562523
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT00561717
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00559650
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 91
- Registration Number
- NCT00558636
© Copyright 2024. All Rights Reserved by MedPath